An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
recurrent and/or unresectable) with measurable disease per RECIST v1.1

- At least 1 lesion accessible for biopsy

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

- Participants with CNS metastases as the only site of active disease (Participants with
controlled brain metastases; however, will be allowed to enroll)

- Participants with active, known or suspected autoimmune disease

- Participants with conditions requiring systemic treatment with either corticosteroids
(> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days
of study treatment administration

- Participants with a known history of testing positive for Human Immunodeficiency Virus
(HIV) or known Acquired Immunodeficiency Syndrome (AIDS)

- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study therapy

Other protocol defined inclusion/exclusion criteria could apply